The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers
Open accessAbstract
A pathological hallmark of Alzheimer's disease is an accumulation of insoluble plaque containing the amyloid-beta peptide of 40-42 amino acid residues. Prefibrillar, soluble oligomers of amyloid-beta have been recognized to be early and key intermediates in Alzheimer's-disease-related synaptic dysfunction. At nanomolar concentrations, soluble amyloid-beta oligomers block hippocampal long-term potentiation, cause dendritic spine retraction from pyramidal cells and impair rodent spatial memory. Soluble amyloid-beta oligomers have been prepared from chemical syntheses, transfected cell culture supernatants, transgenic mouse brain and human Alzheimer's disease brain. Together, these data imply a high-affinity cell-surface receptor for soluble amyloid-beta oligomers on neurons-one that is central to the pathophysiological process in Alzheimer's disease. Here we identify the cellular prion protein (PrP(C)) as an amyloid-beta-oligomer receptor by expression cloning. Amyloid-beta oligomers bind with nanomolar affinity to PrP(C), but the interaction does not require the infectious PrP(Sc) conformation. Synaptic responsiveness in hippocampal slices from young adult PrP null mice is normal, but the amyloid-beta oligomer blockade of long-term potentiation is absent. Anti-PrP antibodies prevent amyloid-beta-oligomer binding to PrP(C) and rescue synaptic plasticity in hippocampal slices from oligomeric amyloid-beta. Thus, PrP(C) is a mediator of amyloid-beta-oligomer-induced synaptic dysfunction, and PrP(C)-specific pharmaceuticals may have therapeutic potential for Alzheimer's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among the Aβ binding candidates, cellular prion protein (PrPc) represents the most studied, either alone or through a complex with mGluR5 [37, 62, 72, 79].”
From Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer’s disease (2024) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most studied binding partner is the PrPc, which through a cascade involving a complex with mGluR5 may lead to toxicity independently or via tau [37, 62, 72, 79].”
From Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer’s disease (2024) · cites this paper as [37]
Experimental — accuracy not yet measuredIn the citing paper
“Aβ binds to α7 nicotinic acetylcholine receptors (α7 nAChRs) and to metabotropic glutamate receptors, in particular mGluR5 [31–33].”
From ApoE, ApoE Receptors, and the Synapse in Alzheimer's Disease (2017) · cites this paper as [33]
In the citing paper
“A genome-wide association study (GWAS) identified PrPC as a potential high-affinity receptor for oAβ [87].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [87]
In the citing paper
“Subsequent studies showed that oAβ, especially high-molecular weight oligomers [88], preferentially bind to PrPC within an N-terminal 95-111aa segment [87].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [87]
In the citing paper
“oligomer binding is significantly reduced in PrPC knock-out cells (Lauren et al., 2009).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lauren et al., 2009
In the citing paper
“Aβ oligomers bind with nanomolar affinity to cellular prion protein (PrPC) and that anti-PrP antibodies reduce oligomer binding to neurons and rescue synaptic plasticity (Lauren et al., 2009).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lauren et al., 2009
In the citing paper
“explaining the finding that knocking-down these proteins or adding antibodies against their extracellular domains blocks the accumulation of ADDL clusters (“hotspots”) at synapses (De Felice et al., 2007; Decker et al., 2010a; Lauren et al., 2009).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lauren et al., 2009
In the citing paper
“PrPC binds synthetic Aβ oligomers with high affinity and plays a role in the oligomer-mediated inhibition of LTP (17).”
From Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein (2010) · cites this paper as [17]
In the citing paper
“In an elegant study Lauren et al. (17) reported that PrPC mediates the Aβ oligomer-induced hippocampal synaptic plasticity impairment.”
From Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein (2010) · cites this paper as [17]
In the citing paper
“The 22 °C-Aβ oligomers impaired recognition memory in both Prnp +/+ and Prnp 0/0 mice (Fig. 4C).”
From Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein (2010) · cites this paper as [17]
In the citing paper
“When amyloid-β oligomers bind to PrPc, long-term potentiation and the formation of new memories are disrupted [129,130,131].”
From Sigma-2 Receptors—From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases (2023) · cites this paper as [130]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Prusiner, S. B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13363 · Cited by 5,373
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012
Natural oligomers of the amyloid-β protein specifically disrupt cognitive function
Cleary, J. P., Walsh, D. M., Hofmeister, J. J., Shankar, G. M., Kuskowski, M. A., Selkoe, D. J., & Ashe, K. H. (2004) · Nature Neuroscience · doi:10.1038/nn1372 · Cited by 1,722
Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein
Büeler, H., Fischer, M., Lang, Y., Bluethmann, H., Lipp, H., DeArmond, S. J., Prusiner, S. B., Aguet, M., & Weissmann, C. (1992) · Nature · doi:10.1038/356577a0 · Cited by 1,678
Shankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., & Sabatini, B. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4970-06.2007 · Cited by 1,592
Flagged first, then by citations
Cited by
Sorted by citations
Items 801–900 of 1,002
Potential Novel Approaches to Understand the Pathogenesis and Treat Alzheimer’s Disease
Drummond, E., Goñi, F., Liu, S., Prelli, F., Scholtzova, H., & Wısnıewskı, T. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179909 · Cited by 26
A d-enantiomeric peptide interferes with heteroassociation of amyloid-β oligomers and prion protein
Rösener, N. S., Gremer, L., Reinartz, E., König, A., Brener, O., Heise, H., Hoyer, W., Neudecker, P., & Willbold, D. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.003116 · Cited by 26
Helal, M., Igel‐Egalon, A., Lakmeche, A., Mazzocco, P., Perrillat-Mercerot, A., Pujo-Menjouet, L., Rezaei, H., & Tine, L. M. (2018) · Journal of Mathematical Biology · doi:10.1007/s00285-018-1267-1 · Cited by 25
Subcellular distribution of the prion protein in sickness and in health
Godsave, S. F., Peters, P. J., & Wille, H. (2015) · Virus Research · doi:10.1016/j.virusres.2015.02.004 · Cited by 25
Benvegnù, S., Roncaglia, P., Agostini, F., Casalone, C., Corona, C., Gustincich, S., & Legname, G. (2011) · Physiological Genomics · doi:10.1152/physiolgenomics.00205.2010 · Cited by 25
Rial, D., Piermartiri, T., Duarte, F. S., Tasca, C. I., Walz, R., & Prediger, R. D. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.04.034 · Cited by 25
Bate, C., Tayebi, M., Diomede, L., Salmona, M., & Williams, A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008221 · Cited by 25
Oropesa‐Nuñez, R., Seghezza, S., Dante, S., Diaspro, A., Cascella, R., Cecchi, C., Stefani, M., Chiti, F., & Canale, C. (2016) · Oncotarget · doi:10.18632/oncotarget.10449 · Cited by 25
DiChiara, T., DiNunno, N., Clark, J. R., Bu, R. L., Cline, E. N., Rollins, M. G., Gong, Y., Brody, D. L., Sligar, S. G., Velasco, P. T., et al. (2017) · PubMed · Cited by 25
The Quest for Cellular Prion Protein Functions in the Aged and Neurodegenerating Brain
Gavı́n, R., Lidón, L., Ferrer, I., & del Rı́o, J. A. (2020) · Cells · doi:10.3390/cells9030591 · Cited by 25
The cellular prion protein beyond prion diseases
Manni, G., Lewis, V., Senesi, M., Spagnolli, G., Fallarino, F., Collins, S. J., Mouillet‐Richard, S., & Biasini, E. (2020) · Swiss Medical Weekly · doi:10.4414/smw.2020.20222 · Cited by 25
Impact of the Cellular Prion Protein on Amyloid-β and 3PO-Tau Processing
Schmitz, M., Wulf, K., Signore, S. C., Schulz‐Schaeffer, W., Kermer, P., Bähr, M., Wouters, F. S., Zafar, S., & Zerr, I. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130566 · Cited by 25
Is indeed the prion protein a Harlequin servant of "many" masters?
Sorgato, M. C., Peggion, C., & Bertoli, A. (2009) · Prion · doi:10.4161/pri.3.4.10012 · Cited by 25
(2011) · Nature Neuroscience · doi:10.1038/nn0411-399 · Cited by 25
Freund, R. K., Gibson, E. S., Potter, H., & Dell’Acqua, M. L. (2016) · Molecular Pharmacology · doi:10.1124/mol.115.103085 · Cited by 24
The Use of Patient-Derived Induced Pluripotent Stem Cells for Alzheimer’s Disease Modeling
Lee, C., Willerth, S. M., & Nygaard, H. B. (2020) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101804 · Cited by 24
Self-citationPrion assemblies: structural heterogeneity, mechanisms of formation, and role in species barrier
Igel‐Egalon, A., Fornara, B., Rézaei, H., & Béringue, V. (2022) · Cell and Tissue Research · doi:10.1007/s00441-022-03700-2 · Cited by 24
Waigi, E. W., Webb, R. C., Moss, M. A., Uline, M. J., McCarthy, C. G., & Wenceslau, C. F. (2023) · GeroScience · doi:10.1007/s11357-023-00748-y · Cited by 26
Kroker, K. S., Moreth, J., Kußmaul, L., Rast, G. F., & Rosenbrock, H. (2013) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2013.04.006 · Cited by 24
Inhibition of human prion neuropeptide PrP106-126 aggregation by hexacoordinated ruthenium complexes
Wang, X., Zhang, B., Zhao, C., Wang, Y., He, L., Cui, M., Zhu, X., & Du, W. (2013) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2013.07.009 · Cited by 24
Brain amyloid β protein and memory disruption in Alzheimer’s disease
Xia, W. (2010) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s7460 · Cited by 24
The Role of Shed Prion Protein (sPrPc) in the Neuropathogenesis of HIV Infection
Megra, B. W., Eugenin, E., & Berman, J. (2017) · Journal of Immunology · doi:10.4049/jimmunol.1601041 · Cited by 23
The Effects of N-terminal Mutations on β-amyloid Peptide Aggregation and Toxicity
Foroutanpay, B. V., Kumar, J., Kang, S., Danaei, N., Westaway, D. A., Sim, V. L., & Kar, S. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.03.014 · Cited by 24
Melatonin in Synaptic Impairments of Alzheimer’s Disease
Shi, Y., Fang, Y., Wei, Y., Jiang, Q., Zeng, P. H., Tang, N., Lu, Y., & Tian, Q. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-171178 · Cited by 24
Yang, M., Wang, K., Lin, J., Wang, L., Wei, F., Zhu, J., Zheng, W., & Shen, L. (2018) · Langmuir · doi:10.1021/acs.langmuir.8b01315 · Cited by 24
Genome‐wide identification of microRNAs regulating the human prion protein
Pease, D., Scheckel, C., Schaper, E., Eckhardt, V., Emmenegger, M., Xénarios, I., & Aguzzi, A. (2018) · Brain Pathology · doi:10.1111/bpa.12679 · Cited by 24
Kawaguchi, K., Kitaguchi, N., Nakai, S., Murakami, K., Asakura, K., Mutoh, T., Fujita, Y., & Sugiyama, S. (2010) · Journal of Artificial Organs · doi:10.1007/s10047-010-0482-3 · Cited by 24
Immunotherapy for Prion Diseases: Opportunities and Obstacles
Li, L., Napper, S., & Cashman, N. R. (2010) · Immunotherapy · doi:10.2217/imt.10.3 · Cited by 24
Levine, Z. A., Teranishi, K., Okada, A. K., Langen, R., & Shea, J. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b04995 · Cited by 23
Aβ43 aggregates exhibit enhanced prion-like seeding activity in mice
Ruiz‐Riquelme, A., Mao, A., Barghash, M. M., Lau, H. H. C., Stuart, E., Kovács, G. G., Nilsson, K. P. R., Fraser, P. E., Schmitt‐Ulms, G., & Watts, J. C. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01187-6 · Cited by 23
Nies, S. H., Takahashi, H., Herber, C. S., Huttner, A. J., Chase, A., & Strittmatter, S. M. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101159 · Cited by 25
Self-citationFyn Kinase in Alzheimer’s Disease: Unraveling Molecular Mechanisms and Therapeutic Implications
Meur, S., & Karati, D. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04286-2 · Cited by 24
Alzheimer disease: update on basic mechanisms.
Bi, X. (2010) · PubMed · Cited by 24
Dual functions of β-amyloid oligomer and fibril in Cu(II)-induced H2O2 production
Fang, C.-L., Wu, W., Liu, Q. R., Sun, X., Ma, Y., Zhao, Y., & Li, Y. (2010) · Regulatory Peptides · doi:10.1016/j.regpep.2010.05.001 · Cited by 23
Kimpe, L. D., & Scheper, W. (2009) · Current Medicinal Chemistry · doi:10.2174/092986710790149765 · Cited by 23
Cells and prions: A license to replicate
Nuvolone, M., Aguzzi, A., & Heikenwälder, M. F. (2009) · FEBS Letters · doi:10.1016/j.febslet.2009.06.014 · Cited by 23
Sod1 Deficiency Reduces Incubation Time in Mouse Models of Prion Disease
Akhtar, S., Grizenkova, J., Wenborn, A., Hummerich, H., de Marco, M. F., Brandner, S., Collinge, J., & Lloyd, S. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054454 · Cited by 23
Andreetto, E., Yan, L., Tatarek‐Nossol, M., Velkova, A., Frank, R., & Kapurniotu, A. (2010) · Angewandte Chemie · doi:10.1002/ange.200904902 · Cited by 23
Fragile X mental retardation protein: from autism to neurodegenerative disease
Wang, H. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00043 · Cited by 26
Iron is a specific cofactor for distinct oxidation- and aggregation-dependent Aβ toxicity mechanisms
Ott, S., Dziadulewicz, N., & Crowther, D. C. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.019042 · Cited by 23
Prion Diagnosis: Application of Real-Time Quaking-Induced Conversion
Kang, H., Mo, Y., Rahim, R. A., Lee, H., & Ryou, C. (2017) · BioMed Research International · doi:10.1155/2017/5413936 · Cited by 23
Amyloid β-induced FOXRED2 mediates neuronal cell death via inhibition of proteasome activity
Shim, S., Lee, W., Chung, H., & Jung, Y. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0561-x · Cited by 23
Could PKR inhibition modulate human neurodegeneration?
Hugon, J., Paquet, C., & Chang, R. C. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.92 · Cited by 23
Feller, B., Fallon, A., Luo, W., Nguyen, P. T., Shlaifer, I., Lee, A. K., Chofflet, N., Yi, N., Khaled, H., Karkout, S., et al. (2023) · Cells · doi:10.3390/cells12071083 · Cited by 22
Prion acute synaptotoxicity is largely driven by protease-resistant PrPSc species
Foliaki, S. T., Lewis, V., Finkelstein, D. I., Lawson, V., Coleman, H. A., Senesi, M., Islam, A. M. T., Chen, F., Sarros, S., Roberts, B. R., et al. (2018) · PLoS Pathogens · doi:10.1371/journal.ppat.1007214 · Cited by 22
Sensing α‐Synuclein From the Outside via the Prion Protein: Implications for Neurodegeneration
Brás, I. C., Lopes, L. V., & Outeiro, T. F. (2018) · Movement Disorders · doi:10.1002/mds.27478 · Cited by 24
Prion protein and prion disease at a glance
Zhu, C., & Aguzzi, A. (2021) · Journal of Cell Science · doi:10.1242/jcs.245605 · Cited by 27
Lipid Rafts Act as a Common Platform for Amyloid-β Oligomer-Induced Alzheimer’s Disease Pathology
Kawarabayashi, T., Nakamura, T., Sato, K., Seino, Y., Ichii, S., Nakahata, N., Takatama, M., Westaway, D. A., George‐Hyslop, P. S., & Shoji, M. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215662 · Cited by 22
Ribeiro, L. W., Pietri, M., Ardila-Osorio, H., Baudry, A., Boudet-Devaud, F., Bizingre, C., Arellano-Anaya, Z. E., Haeberlé, A., Gadot, N., Boland, S., et al. (2022) · Particle and Fibre Toxicology · doi:10.1186/s12989-022-00490-x · Cited by 22
Huc-Brandt, S., Hieu, N., Imberdis, T., Cubedo, N., Silhol, M., Leighton, P. L. A., Domaschke, T., Allison, W. T., Perrier, V., & Rossel, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113331 · Cited by 22
Globular and Protofibrillar Aβ Aggregates Impair Neurotransmission by Different Mechanisms
Moreth, J., Kroker, K. S., Schwanzar, D., Schnack, C., Arnim, C. A. F. V., Hengerer, B., Rosenbrock, H., & Kußmaul, L. (2013) · Biochemistry · doi:10.1021/bi3016444 · Cited by 24
Mario, A. D., Peggion, C., Massimino, M. L., Norante, R. P., Zulian, A., Bertoli, A., & Sorgato, M. C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184640 · Cited by 22
Bacchella, C., Nicolis, S., Dell’Acqua, S., Rizzarelli, E., Monzani, E., & Casella, L. (2019) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.9b03153 · Cited by 23
Mashima, T., Lee, J., Kamatari, Y. O., Hayashi, T., Nagata, T., Nishikawa, F., Nishikawa, S., Kinoshita, M., Kuwata, K., & Katahira, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-61966-4 · Cited by 22
Mosaic Somatic Gene Recombination as a Potentially Unifying Hypothesis for Alzheimer’s Disease
Kaeser, G. E., & Chun, J. J. M. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00390 · Cited by 23
Hong, H.-S., Maezawa, I., Petrlova, J., Zhao, X.-Y., C. Voss, J., & Jin, L.-W. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150318 · Cited by 23
Manipulating the Prion Protein Gene Sequence and Expression Levels with CRISPR/Cas9
Kaczmarczyk, L., Mende, Y., Zevnik, B., & Jackson, W. S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154604 · Cited by 22
β‐Amyloid 1‐42 induces physiological transcriptional regulation of BACE1
Piccini, A., Borghi, R., Guglielmotto, M., Tamagno, E., Cirmena, G., Garuti, A., Pollero, V., Cammarata, S., Fornaro, M., Messa, M., et al. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07834.x · Cited by 22
Bobkova, N. V., Medvinskaya, N. I., Kamynina, A. V., Aleksandrova, I. Y., Nesterova, I. V., Samokhin, A. N., Koroev, D. O., Филатова, М. П., Nekrasov, P. V., Abramov, A. Y., et al. (2013) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2013.10.019 · Cited by 21
Tangeretin Inhibits BACE1 Activity and Attenuates Cognitive Impairments in AD Model Mice
Bao, J., Liang, Z., Gong, X., Zhao, Y., Wu, M., Liu, W., Tu, C., Wang, X., & Shu, X. (2022) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.1c07241 · Cited by 21
The prion protein and its ligands: Insights into structure-function relationships
Shafiq, M., Vela, S. D., Amin, L., Younas, N., Harris, D. A., Zerr, I., Altmeppen, H. C., Svergun, D. I., & Glatzel, M. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2022.119240 · Cited by 21
Alzheimer’s disease is an inherent, natural part of human brain aging: an integrated perspective
Ferrer, I. (2022) · Free Neuropathology · doi:10.17879/freeneuropathology-2022-3806 · Cited by 25
Neuroimaging Through the Course of Alzheimer's Disease
Smith, C. D. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1217 · Cited by 22
Shedding light on prion disease
Glatzel, M., Linsenmeier, L., Dohler, F., Krasemann, S., Puig, B., & Altmeppen, H. C. (2015) · Prion · doi:10.1080/19336896.2015.1065371 · Cited by 22
Regulation of amyloid-β production by the prion protein
Jarosz-Griffiths, H., Whitehouse, I. J., & Hooper, N. M. (2012) · Prion · doi:10.4161/pri.18988 · Cited by 23
N-terminal Domain of Prion Protein Directs Its Oligomeric Association
Trevitt, C. R., Hosszu, L. L. P., Batchelor, M., Panico, S., Terry, C., Nicoll, A. J., Risse, E., Taylor, W. A., Sandberg, M. K., Al-Doujaily, H., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.566588 · Cited by 21
Possible role for Ca2+ in the pathophysiology of the prion protein?
Peggion, C., Bertoli, A., & Sorgato, M. C. (2011) · BioFactors · doi:10.1002/biof.161 · Cited by 21
The Role of Activity in Synaptic Degeneration in a Protein Misfolding Disease, Prion Disease
Caleo, M., Restani, L., Vannini, E., Šišková, Z., Al-Malki, H., Morgan, R. S. M., O'Connor, V. M., & Perry, V. H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041182 · Cited by 21
Gold complexes inhibit the aggregation of prion neuropeptides
Wang, X., He, L., Zhao, C., Du, W., & Lin, J. X. (2013) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-013-1030-4 · Cited by 21
Puig, B., Altmeppen, H. C., Thurm, D., Geissen, M., Conrad, C., Braulke, T., & Glatzel, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024624 · Cited by 21
Hijacking PrPc-dependent signal transduction: when prions impair Aβ clearance
Hernandez-Rapp, J., Martin‐Lannerée, S., Hirsch, T. Z., Launay, J., & Mouillet‐Richard, S. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00025 · Cited by 24
Dual role of cellular prion protein in normal host and Alzheimer’s disease
Onodera, T. (2017) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.93.010 · Cited by 22
Taricska, N., Horváth, D., Menyhárd, D. K., Ákontz‐Kiss, H., Noji, M., So, M., Goto, Y., Fujiwara, T., & Perczel, A. (2019) · Chemistry - A European Journal · doi:10.1002/chem.201903826 · Cited by 21
The multiple functions of the co-chaperone stress inducible protein 1
da Fonseca, A. C. C., Matias, D., Geraldo, L. H., Leser, F. S., Pagnoncelli, I., Garcia, C., do Amaral, R. F., da Rosa, B. G., Grimaldi, I., Magalhães, E. S. D. C., et al. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.06.003 · Cited by 21
A New Take on Prion Protein Dynamics in Cellular Trafficking
Alves, R. N., Iglesia, R. P., Prado, M. B., Melo-Escobar, M. I., Boccacino, J. M., Fernandes, C. F. D. L., Coelho, B. P., Fortes, A. C. D. S., & Lopes, M. H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207763 · Cited by 21
Role of Fyn Kinase Inhibitors in Switching Neuroinflammatory Pathways
Marotta, G., Basagni, F., Rosini, M., & Minarini, A. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867329666211221153719 · Cited by 21
Unraveling the neuroprotective mechanisms of PrP C in excitotoxicity
Llorens, F., & del Rı́o, J. A. (2012) · Prion · doi:10.4161/pri.19639 · Cited by 21
Santis, E. D., Minicozzi, V., Proux, O., Rossi, G. C., Silva, K. I., Lawless, M. J., Stellato, F., Saxena, S., & Morante, S. (2015) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.5b10264 · Cited by 21
Dimerization of the cellular prion protein inhibits propagation of scrapie prions
Engelke, A. D., Gonsberg, A., Thapa, S., Jung, S., Ulbrich, S., Seidel, R. P., Basu, S., Multhaup, G., Baier, M., Engelhard, M., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.000990 · Cited by 20
The multiple functions of PrPC in physiological, cancer, and neurodegenerative contexts
Grimaldi, I., Leser, F. S., Janeiro, J. M., da Rosa, B. G., Campanelli, A. C., Romão, L. F., & Lima, F. R. S. (2022) · Journal of Molecular Medicine · doi:10.1007/s00109-022-02245-9 · Cited by 21
Cofilin promotes tau pathology in Alzheimer’s disease
Yan, M., Tang, L., Dai, L., Lei, C., Xiong, M., Zhang, X., He, M., Tian, Y., Xiong, J., Ke, W., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112138 · Cited by 20
Qiu, W., Liu, H., Liu, Y., Lü, X., Wang, L., Hu, Y., Feng, F., Li, Q., & Sun, H. (2023) · Medicinal Research Reviews · doi:10.1002/med.21947 · Cited by 20
Evidence that Alzheimer’s Disease Is a Disease of Competitive Synaptic Plasticity Gone Awry
Huang, Z. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240042 · Cited by 20
N-homocysteinylation of ovine prion protein induces amyloid-like transformation
Stroylova, Y. Y., Chobert, J., Muronetz, V. I., Jakubowski, H., & Haertlé, T. (2012) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2012.06.008 · Cited by 20
Regulation of PrPC signaling and processing by dimerization
Roucou, X. (2014) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2014.00057 · Cited by 20
Williams, T. L., Choi, J.-K., Surewicz, K. A., & Surewicz, W. K. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00229 · Cited by 20
Inhibition of Aβ42 oligomerization in yeast by a PICALM ortholog and certain FDA approved drugs
Park, S.-K., Ratia, K. M., Ba, M. A., Valencik, M. L., & Liebman, S. W. (2016) · Microbial Cell · doi:10.15698/mic2016.02.476 · Cited by 21
Mario, A. D., Peggion, C., Massimino, M. L., Viviani, F., Castellani, A., Giacomello, M., Lim, D., Bertoli, A., & Sorgato, M. C. (2017) · Journal of Cell Science · doi:10.1242/jcs.196972 · Cited by 21
Evans, E. G. B., & Millhauser, G. L. (2017) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2017.06.005 · Cited by 20
The prion protein in neuroimmune crosstalk
Salvesen, Ø., Tatzelt, J., & Tranulis, M. A. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2018.11.010 · Cited by 20
Madhu, P., & Mukhopadhyay, S. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00646 · Cited by 20
Mohammadi, B., Linsenmeier, L., Shafiq, M., Puig, B., Galliciotti, G., Giudici, C., Willem, M., Eden, T. W., Koch‐Nolte, F., Lin, Y.-H., et al. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-01917-2 · Cited by 20
Arnould, H., Baudouin, V., Baudry, A., Ribeiro, L. W., Ardila-Osorio, H., Pietri, M., Caradeuc, C., Soultawi, C., Williams, D., Alvarez, M., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009991 · Cited by 20
To develop with or without the prion protein
Halliez, S., Passet, B., Martin‐Lannerée, S., Hernandez-Rapp, J., Laude, H., Mouillet‐Richard, S., Vilotte, J.-L., & Béringue, V. (2014) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2014.00058 · Cited by 20
Lipid rafts: linking prion protein to zinc transport and amyloid-β toxicity in Alzheimer's disease
Watt, N. T., Jarosz-Griffiths, H., & Hooper, N. M. (2014) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2014.00041 · Cited by 22
Effect of ferric citrate on amyloid‐beta peptides behavior
Galante, D., Cavallo, E., Perico, A., & D’Arrigo, C. (2018) · Biopolymers · doi:10.1002/bip.23224 · Cited by 20
Spatiotemporal Regulation of Signaling In and Out of Dendritic Spines: CaMKII and Ras
Lee, S.-J. R., & Yasuda, R. (2009) · The Open Neuroscience Journal · doi:10.2174/1874082000903020117 · Cited by 21
Unaltered prion protein expression in Alzheimer disease patients
Saijo, E., Scheff, S. W., & Telling, G. C. (2011) · Prion · doi:10.4161/pri.5.2.16355 · Cited by 19
Cellular prion protein modulates β-amyloid deposition in aged APP/PS1 transgenic mice
Ordóñez‐Gutiérrez, L., Torres, J. M., Gavı́n, R., Antón, M., Arroba, A. I., Espinosa, J. C., Vergara, C., del Rı́o, J. A., & Wandosell, F. G. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.05.019 · Cited by 19
Immunomodulation for prion and prion-related diseases
Wısnıewskı, T., & Goñi, F. (2010) · Expert Review of Vaccines · doi:10.1586/erv.10.131 · Cited by 19
Metadata
- Authors
- Laurén, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W., & Strittmatter, S. M.
- Affiliations
- Yale University (US)
- Corresponding author
- Strittmatter, Stephen M.
- Venue
- Nature
- Published
- 2009-02
- Volume
- 457
- Issue
- 7233
- Pages
- 1128-1132
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2748841
- OpenAlex
- W2171526610
- Cited by
- 1,560
- References
- 37
- Citations by year
- 2026: 46 · 2025: 45 · 2024: 50 · 2023: 52 · 2022: 87 · 2021: 82 · 2020: 85 · 2019: 71 · 2018: 108 · 2017: 117 · 2016: 103 · 2015: 98 · 2014: 104 · 2013: 116 · 2012: 119
- FWCI
- 87.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- U.S. Public Health Service (5T32GN07205)
- National Institute on Drug Abuse (P30DA018343)
- National Institute of Neurological Disorders and Stroke (R01NS042304, R01NS039962, R37NS033020)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Prion Diseases and Protein Misfolding
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- cellular prion protein, amyloid-beta oligomers, Alzheimer's disease, synaptic plasticity, long-term potentiation, cell surface receptors, lipid rafts, hippocampus, anti-PrP antibodies, prion disease, expression cloning, neurotoxicity, spatial memory, neuroprotection, neurodegeneration
- MeSH terms
- Alzheimer Disease, Amyloidosis, Animals, Chlorocebus aethiops, Hippocampus, Humans, Mice, Inbred C57BL, Neuronal Plasticity, Neurons, Peptide Fragments, Prions, Protein Binding, Receptors, Cell Surface, Synapses, Amyloid beta-Peptides, Long-Term Potentiation, COS Cells, Mice, Amyloid Precursor Protein Secretases, Protein Multimerization
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
